Last C$0.52 CAD
Change Today 0.00 / 0.00%
Volume 0.0
IGX On Other Exchanges
Symbol
Exchange
OTC US
Venture
As of 9:41 AM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

intelgenx technologies corp (IGX) Snapshot

Open
C$0.52
Previous Close
C$0.52
Day High
C$0.52
Day Low
C$0.52
52 Week High
02/3/14 - C$1.33
52 Week Low
11/18/13 - C$0.46
Market Cap
33.0M
Average Volume 10 Days
2.6K
EPS TTM
--
Shares Outstanding
63.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTELGENX TECHNOLOGIES CORP (IGX)

Related News

No related news articles were found.

intelgenx technologies corp (IGX) Related Businessweek News

No Related Businessweek News Found

intelgenx technologies corp (IGX) Details

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. Its product portfolio comprises INT0001/2004 for coronary heart failure and hypertension; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2007 for the treatment of migraine; INT0024/2010 for idiopathic pulmonary fibrosis; INT0027/2011 for opioid dependence; INT0028/2011 for cancer pain; INT0030/2011 for animal health; and INT0036/2012 for central nervous system disorders, as well as INT0037/2013 and INT0039/2013. The company develops its products based on three delivery platform technologies, which consist of the Multilayer Tablet technology that allows for the development of oral controlled-release products; the Oral Film technology, which allows for the delivery of pharmaceuticals to the oral cavity; and the Mucoadhesive Tablet technology for the controlled release of active substances to the oral mucosa. It also provides product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets. The company has a strategic alliance with LTS Lohmann Therapie-Systeme AG to manufacture pharmaceutical products using VersaFilm drug delivery technology; and a strategic manufacturing partnership with Pillar5 Pharma Inc. IntelGenx Technologies Corp. also has a co-development and commercialization agreement with RedHill Biopharma Ltd. for the co-development and commercialization of INT0008/2007. IntelGenx Technologies Corp. was founded in 2003 and is based in Ville Saint Laurent, Canada.

12 Employees
Last Reported Date: 03/11/14
Founded in 2003

intelgenx technologies corp (IGX) Top Compensated Officers

Chairman of the Board, Interim Chief Executiv...
Total Annual Compensation: $261.4K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $230.5K
Compensation as of Fiscal Year 2013.

intelgenx technologies corp (IGX) Key Developments

IntelGenx Technologies Corp. Announces Financial Results for the Second Quarter and Six Months Ended June 30, 2014

IntelGenx Technologies Corp. announced financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net cash used in operating activities of $1.2 million compared to $0.3 million reported in the same period last year. Revenue of $0.4 million during the six months ended June 30, 2014 compared to $0.7 million reported in the same period last year. Revenues of current period primarily relates to revenue generated by Forfivo XL(R). Net loss increased from $0.4 million in the first six months of 2013 to $1.1 million in the same period of 2014. The loss per share was $0.01 in the first six months of 2013 and $0.02 in the first six months of 2013.

IntelGenx Technologies Corp. - Special Call

To provide a business update and discussion regarding the company's recent management changes

IntelGenx Technologies Corp. Announces Management Changes

IntelGenx Technologies Corp. announced that the board of directors has accepted, with immediate effect, the resignation of Dr. Rajiv Khosla as President and Chief Executive Officer of IntelGenx and as a member of the board. Effective immediately, the board has appointed Dr. Horst G. Zerbe to serve as IntelGenx' interim President and CEO until a successor is found. A Search Committee has been formed by the Board to begin the search, selection and appointment of a new President and CEO. Dr. Zerbe is the Chairman of the Board, founder, and former President and CEO of the company. He retired from the positions of President and CEO effective December 31, 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IGX:CN C$0.52 CAD 0.00

IGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $17.02 USD -0.33
View Industry Companies
 

Industry Analysis

IGX

Industry Average

Valuation IGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 47.9x
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 39.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTELGENX TECHNOLOGIES CORP, please visit www.intelgenx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.